Accès à distance ? S'identifier sur le proxy UCLouvain
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Primary tabs
- Open access
- 720.42 K
Document type | Article de périodique (Journal article) – Article de recherche |
---|---|
Access type | Accès libre |
Publication date | 2020 |
Language | Anglais |
Journal information | "Trials" - Vol. 21, no.1, p. 981 [1-15] (2020) |
Peer reviewed | yes |
Publisher | BioMed Central ((United Kingdom) London) |
e-issn | 1745-6215 |
Publication status | Publié |
Affiliations |
UCL
- SSS/IREC/SLUC - Pôle St.-Luc UCL - (SLuc) Service de médecine interne et maladies infectieuses (MIMI) |
MESH Subject | Adult ; Antibodies, Viral ; Belgium ; COVID-19 ; Combined Modality Therapy ; Female ; Global Burden of Disease ; Hospitalization ; Humans ; Immunization, Passive ; Male ; Mortality ; Respiration, Artificial ; SARS-CoV-2 ; Safety ; Standard of Care ; Treatment Outcome |
Keywords | Antibodies ; COVID-19 ; Convalescent plasma ; Immunity ; SARS-CoV-2 |
Links |
Bibliographic reference | Devos, Timothy ; Geukens, Tatjana ; Schauwvlieghe, Alexander ; Ariën, Kevin K ; Barbezange, Cyril ; et. al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.. In: Trials, Vol. 21, no.1, p. 981 [1-15] (2020) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/253877 |